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Background: The aim of this study was to evaluate the safety and survival outcomes of anti-programmed 
cell death (PD)-1/programmed cell death-ligand 1 (PD-L1) monotherapy in patients with advanced non-
small cell lung cancer (NSCLC) and different hepatitis B virus (HBV) infection status. 
Methods: Patients with advanced NSCLC and both chronic and/or resolved HBV infection who were 
treated with anti-PD-(L)1 monotherapy were retrospectively enrolled. The primary endpoint was the safety 
of PD-1/PD-L1 monotherapy, while the secondary endpoints included the survival outcomes.
Results: Of the 62 eligible patients, 10 (16.1%) were hepatitis B surface antigen (HBsAg) positive [chronic 
hepatitis B (CHB) infection] and 52 (83.9%) were HBsAg negative and HBcAb positive [resolved hepatitis 
B (RHB) infection]; 42 (67.7%) patients had at least 1 treatment-related adverse event (AE), with 4 patients 
(6.5%) developing grade 3 AEs and 6 (9.7%) developing hepatic AEs. One CHB patient experienced HBV 
reactivation during anti-PD-1 immunotherapy due to the interruption of antiviral prophylaxis. The objective 
response rate and durable clinical benefit (DCB) rate were 17.7% and 29.0%, respectively. Median overall 
survival (OS) and progression-free survival (PFS) were 23.6 months [95% confidence interval (CI): 14.4–
32.8] and 2.1 months (95% CI: 1.2–3.0), respectively. The DCB rate was significantly higher in the CHB 
group than in the RHB group (60% vs. 23.1%; P=0.048). Patients with CHB experienced a longer PFS (8.3 
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Introduction
Lung cancer remains the leading cause of cancer-
associated mortality (1). Recently, anti-programmed cell 
death 1 (PD-1) and anti-programmed cell death-ligand 1 
(PD-L1) blockade have revolutionized the treatment of 
various malignancies, including non-small cell lung cancer 
(NSCLC). Several PD-(L)1 pathway inhibitors have been 
approved for second-line treatment of advanced NSCLC 
patients after progression on platinum-based therapy (2-5). 
For patients with high PD-L1 expression, pembrolizumab, 
atezolizumab, and cemiplimab have replaced platinum 
doublet chemotherapy as the first-line treatment with 
a better toxicity profile while retaining survival benefit 
(6-8). However, patients with NSCLC and some concurrent 
infections, including human immunodeficiency virus (HIV) 
infection and hepatitis B/C infection, were excluded from 
most clinical trials of immunotherapy. Recently, some 
retrospective studies or prostective clinical trials have 
demonstrated that the efficacy and limited toxicity of PD-
(L)1 inhibitors in patients with HIV infection and advanced 
NSCLC is similar to non-infected patients (9-13). However, 
data from the literature have been limited to case reports or 
small case series that have described the utilization of PD-1 
pathway inhibitor (alone or in combination with ipilimumab 
or chemotherapy) for advanced NSCLC patients with 
chronic or previous HBV infection (14-20). Therefore, 
there is a paucity of information on the safety and efficacy 
of anti-PD-(L)1 monotherapy in this population. 
More than 350 million people are chronically infected 
with HBV worldwide (21,22). Apart from being involved 
in cancer immune evasion (23), the PD-1/PD-L1 axis also 
plays a role in chronic hepatitis virus infection. Previous 
studies have shown that PD-1 upregulation is associated 
with HBV-specific T cell dysfunction (24,25), while tumoral 
PD-L1 expression in hepatocellular carcinoma has been 
associated with circulating HBV load (26). For NSCLC, 
PD-L1 expression has also been reported to be significantly 
higher in patients with chronic HBV infection than in 
those without HBV infection (27). Safety is another critical 
concern. In our previous study, HBV reactivation occurred 
in a subset of patients with cancer and positive hepatitis 
B surface antigen (HBsAg) during or after anti-PD-(L)1 
therapy (6 out of 114 patients) (28).
Considering the scale of HBV infection in the global 
population, the under representation of HBV-infected 
patients in clinical trials, the potential association between 
PD-L1 expression and HBV infection, and the related 
safety issues, we conducted this retrospective study to 
explore whether PD-1 pathway inhibitors are safe and 
effective in patients with advanced NSCLC and different 
HBV infection status. We present the following article in 
accordance with the STROBE reporting checklist (available 
at https://dx.doi.org/10.21037/tlcr-21-455).
Methods
Between January 2015 and September 2018, a total of 174 
patients with advanced NSCLC who received anti-PD-
(L)1 monotherapy in Sun Yat-sen University Cancer Center 
were screened. The inclusion criteria were as follows: (I) 
pathologically diagnosed with NSCLC; (II) stage IIIB or 
IV NSCLC or recurrent NSCLC after radical treatment; 
(III) received at least 1 cycle of anti-PD-(L)1 monotherapy; 
(IV) serum HBsAg positive or HBsAg negative and hepatitis 
B core antibody (HBcAb) positive; and (V) with complete 
clinical and survival data. Patients were excluded if they 
had other positive viral markers including immunoglobin 
M (IgM) antibody to hepatitis A virus, antibody to hepatitis 
C virus (HCV), IgG antibody to hepatitis D virus, IgM 
antibody to hepatitis E virus, or antibody to human 
vs. 2.0 months; P=0.103) and OS (35.0 vs. 18.2 months, P=0.119) than did RHB patients. 
Conclusions: Anti-PD-(L)1 monotherapy was safe and effective in patients with NSCLC and HBV 
infection. This population should not be excluded from receiving immunotherapy in routine clinical practice 
or within clinical trials if HBV biomarkers are monitored and antiviral prophylaxis is properly used.
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immunodeficiency virus.
Clinicopathologic data and treatment outcomes were 
retrospectively collected. All patients were followed up 
by outpatient reviews or by telephone conversations, 
with the last  fol low-up date being June 1,  2019. 
Response to treatment was assessed with Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria 
version 1.1 (29) by senior radiologists blinded to patients’ 
data, and consisted of complete response (CR), partial 
response (PR), stable disease (SD), and progressive disease 
(PD). Follow-up computed tomography (CT) scans were 
performed according to the physicians’ discretion without 
predetermined intervals. Objective response was defined as 
complete or partial response, disease control was defined 
as CR + PR + SD, and durable clinical benefit (DCB) was 
defined as survival without disease progression at 24 weeks. 
Progression-free survival (PFS) was defined as the time 
from the initiation of anti-PD-(L)1 monotherapy to the date 
of disease progression or death from any causes. Overall 
survival (OS) was defined as the time from the beginning 
of anti-PD-(L)1 monotherapy to the date of death from 
any causes. Treatment-related adverse events (AEs) were 
assessed according to the Common Terminology Criteria 
for Adverse Events (CTCEA) version 4.0. HBV reactivation 
was defined according to the American Association for 
the Study of Liver Diseases (AASLD) 2018 hepatitis B 
guidance (30) and included the following: (I) a ≥2 log 
(100-fold) increase in HBV DNA compared to the baseline 
level, (II) HBV DNA ≥3 log (1,000) IU/mL in a patient 
with a previously undetectable level, or (III) HBV DNA 
≥4 log (10,000) IU/mL if the baseline level was not 
available.
The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). This study 
was approved by the Sun Yat-sen University Cancer Center 
Institutional Review Board (No. B2020-402-01), and the 
need for informed consent (written or verbal) was waived.
Statistical analysis 
The primary endpoint of this study was the safety and 
tolerability of PD-(L)1 inhibitors in HBV-infected patients 
with advanced NSCLC. The secondary endpoint was the 
antitumor activity of PD-(L)1 inhibitors in this population, 
including overall response rate (ORR), disease control rate 
(DCR), DCB rate, PFS and OS. Baseline characteristics 
were tabulated and summarized. All treatment-related 
AEs that could be possibly attributed to anti-PD-(L)1 
immunotherapy were tabulated. The Pearson χ2 or Fisher 
exact test was used to investigate the relationships between 
categorical variables. Survival analyses were performed 
using the Kaplan-Meier method with log-rank test. A 
2-tailed P value of ≤0.05 was used to determine statistical 
significance. All statistical analyses were performed using 
SPSS version 22.0 (IBM, Armonk, NY, USA).
Results
Patients
A total of 62 eligible patients were included in the analysis. 
Baseline characteristics of the patients are summarized in 
Table 1. All of the 62 patients were Asian. The median age 
was 55 (range, 33–77) years, and 45 (72.6%) patients were 
male. In terms of the histology subtype, 38 (61.3%) patients 
had adenocarcinoma, 20 (32.3%) patients had squamous cell 
carcinoma, and 4 (6.4%) patients had lymphoepithelioma-
like carcinoma; 25 patients (40.3%) were current or former 
smokers, 60 (96.8%) had an Eastern Cooperative Oncology 
Group (ECOG) performance status 0 or 1; 10 patients 
(16.1%) were HBsAg positive [chronic hepatitis B (CHB) 
infection], while 52 patients (83.9%) were HBsAg negative 
and HBcAb positive [resolved hepatitis B (RHB) infection]. 
Of the 10 patients with CHB, 9 (90.0%) patients had a 
baseline HBV DNA quantification which was undetectable, 
with 8 of these patients being on antiviral prophylaxis prior 
to and during PD-1 axis inhibition (6 patients received 
entecavir and 2 received lamivudine). Of the 52 patients 
with RHB, only 6 (11.5%) had baseline HBV DNA data and 
all were undetectable, with none of these patients receiving 
antiviral prophylaxis. Before anti-PD-(L)1 monotherapy, 
57 (91.9%) had received previous systemic therapy, and the 
median number of previous lines of therapy was 1 (range, 
0–7). Only 8 patients had a quantifiable tumor PD-L1 
expression with the 22C3 assay, and 4 of them had a PD-L1 
expression ≥1%.
Safety outcomes
Treatment-related AEs are listed in Table 2. In the overall 
population, 42 (67.7%) of 62 patients had at least 1 
treatment-related AE. The most common AEs of any grade 
were reactive capillary hemangiomas (n=15, 24.2%, related 
to camrelizumab only), rash (n=14, 22.6%), fatigue (n=13, 
21.0%), fever (n=8, 12.9%), hypothyroidism (n=7, 11.3%), 
alanine aminotransferase (ALT) increase (n=6, 9.7%), and 
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Median age [range], years 55 [33–77] 55 [38–66] 57 [33–77]
Sex
Male 45 (72.6) 7 (70.0) 38 (73.1)
Female 17 (27.4) 3 (30.0) 14 (26.9)
Histologic status
Adenocarcinoma 38 (61.3) 7 (70.0) 31 (59.6)
Squamous cell carcinoma 20 (32.3) 3 (30.0) 17 (32.7)
Lymphoepithelioma-like carcinoma 4 (6.4) 0 (0) 4 (7.7)
Stage
IIIB 1 (1.6) 0 (0) 1 (1.9)
IV 61 (98.4) 10 (100.0) 51 (98.1)
ECOG performance status
0 29 (46.8) 4 (40.0) 25 (48.1)
1 31 (50.0) 6 (60.0) 25 (48.1)
2 2 (3.2) 0 (0) 2 (3.8)
Smoking status
Current or former 25 (40.3) 4 (40.0) 21 (40.4)
Never 37 (59.7) 6(60.0) 31 (59.6)
Liver involvement
Yes 15 (24.2) 6 (60.0) 9 (17.3)
No 47 (75.8) 4 (40.0) 43 (82.7)
Baseline HBV DNA level
Undetectablea 15 (21.0) 9 (90.0) 6 (11.5)
Detectable 1 (1.6) 1 (10.0) 0 (0)
Unknown 46 (77.4) 0 (0) 46 (88.5)
Treatment
PD-1 inhibitor monotherapyb 56 (90.3) 10 (100.0) 46 (88.5)
PD-L1 inhibitor monotherapyc 6 (9.7) 0 (0) 6 (11.5)
Previous lines of therapy for advanced disease
0 5 (8.1) 0 (0) 5 (9.6)
1 38 (61.3) 6 (60.0) 32 (61.5)
2 10 (16.1) 3 (20.0) 7 (13.5)
3 or more 9 (14.5) 1 (10.0) 8 (15.4)
Antiviral prophylaxis
Yes 9 (14.5) 8 (80.0) 0 (0)
No 53 (85.5) 2 (20.0) 52 (100.0)
a, HBV DNA <10 IU/mL; b, included pembrolizumab, nivolumab, and camrelizumab; c, atezolizumab. HBsAg, hepatitis B surface antigen; 
HBcAb, hepatitis B core antibody; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; PD-1, programmed cell death 
protein-1; PD-L1, programmed cell death-ligand 1.
3195Translational Lung Cancer Research, Vol 10, No 7 July 2021
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(7):3191-3202 | https://dx.doi.org/10.21037/tlcr-21-455
Table 2 Treatment-related adverse events at least possibly related to PD-1/PD-L1 immunotherapy
Event Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Total, n (%)
Anya 22 (35.5) 16 (25.9) 4 (6.5) 42 (67.7)
Reactive capillary hemangiomas 9 (14.5) 6 (9.7) 0 15 (24.2)
Rash 8 (12.9) 6 (9.7) 0 14 (22.6)
Fatigue 9 (14.5) 3 (4.8) 1 (1.6) 13 (21.0)
Fever 6 (9.7) 2 (3.2) 0 8 (12.9)
Hypothyroidism 5 (8.1) 2 (3.2) 0 7 (11.3)
ALT increase 4 (6.5) 1 (1.6) 1 (1.6) 6 (9.7)
AST increase 4 (6.5) 1 (1.6) 1 (1.6) 6 (9.7)
Pruritus 4 (6.5) 0 0 4 (6.5)
Diarrhea 3 (4.8) 0 0 3 (4.8)
Hypocortisolism 2 (3.2) 1 (1.6) 0 3 (4.8)
Dizziness 3 (4.8) 0 0 3 (4.8)
Anorexia 3 (4.8) 0 0 3 (4.8)
Stomatitis 2 (3.2) 0 0 2 (3.2)
Hyperthyroidism 2 (3.2) 0 0 2 (3.2)
Peripheral neuropathy 0 0 1 (1.6) 1 (1.6)
Myasthenia Gravis 0 0 1 (1.6) 1 (1.6)
Anemia 1 (1.6) 0 0 1 (1.6)
Nausea 1 (1.6) 0 0 1 (1.6)
Constipation 1 (1.6) 0 0 1 (1.6)
Total bilirubin increase 1 (1.6) 0 0 1 (1.6)
Unconjugated bilirubin increase 1 (1.6) 0 0 1 (1.6)
Myalgia 1 (1.6) 0 0 1 (1.6)
Nephritis 0 1 (1.6) 0 1 (1.6)
a, worst per patient. ALT, alanine aminotransferase; AST, aspartate aminotransferase; PD-1, programmed cell death protein-1; PD-L1, 
programmed cell death-ligand 1.
aspartate aminotransferase (AST) increase (n=6, 9.7%). 
Although most AEs were grade 1 or 2 (n=38, 61.3%), 4 
(6.5%) patients developed grade 3 AEs, including 1 case 
of peripheral neuropathy, 1 case of myasthenia gravis, 
1 case of ALT and AST increase, and 1 case of fatigue. 
All grades of hepatic AEs occurred in 6 (9.7%; grade 
1–2 in 5 patients and grade 3 in 1 patient) patients, all of 
whom experienced laboratory abnormalities without any 
symptoms. Immunotherapy was permanently discontinued 
in 3 (4.8%) patients due to treatment-related AEs, and 
no treatment-related death occurred during the study 
period. No significant differences were found in any grade 
of AEs between patients with CHB and RHB; however, 
the incidence of hepatic AEs was significantly higher in 
the CHB group than in the RHB group (50% vs. 1.9%; 
P<0.001; Table 3). 
Immunotherapy-related HBV reactivation
Among the 10 patients with CHB, serum HBV DNA was 
monitored every 1 to 3 months according to the decision 
of the treating physician. One (10%) patient experienced 
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HBV reactivation during the study period. For the other 9 
patients, their HBV DNA level kept undetectable during 
the whole study period. Of the 52 patients with RHB, no 
one developed HBsAg reverse seroconversion.
The patient was a 41-year-old woman diagnosed with 
stage IV NSCLC in July 2014. She began camrelizumab 
monotherapy in December 2016 following progression 
with carboplatin and pemetrexed. She had previously 
been diagnosed with a chronic HBV infection with an 
unknown HBV DNA level. Her baseline HBV DNA level 
in the month before treatment with camrelizumab was 
40.6 IU/mL. Camrelizumab administration was commenced 
in December 2016 along with entecavir antiviral therapy. 
In February 2017, after 2 months of camrelizumab and 
entecavir treatment, a repeat HBV viral load showed 
undetectable DNA. The patient continued entecavir therapy 
and maintained an undetectable HBV DNA level until the 
25th cycle of camrelizumab treatment in October 2017, at 
which time she stopped entecavir against the physician’s 
recommendation. After 36 cycles of camrelizumab, a rise 
in ALT to 530.3 U/L and AST to 312.0 U/L was noticed 
on July 2, 2018. Total bilirubin and alkaline phosphatase 
remained within normal ranges. The HBV DNA level 
increased to 2.18×103 IU/mL, confirming the occurrence 
of HBV reactivation. Consequently, camrelizumab was 
discontinued and entecavir was reintroduced. ALT and 
AST started to trend downward immediately after entecavir 
administration, reaching grade 1- in a 2-week period. HBV 
DNA returned to an undetectable level after 5 weeks. The 
patient resumed camrelizumab after 4 weeks of interruption 
without any further significant AEs occurring.
Efficacy
In all, 56 of 62 patients (90.3%) received PD-1 inhibitor 
(pembrolizumab, nivolumab, and camrelizumab) and 6 
patients (9.7%) received PD-L1 inhibitor (atezolizumab). 
The median duration of PD-(L)1 inhibitor treatment was 
10 weeks (range, 1–157 weeks). With a median follow-up 
time of 28.4 months (range, 0.6–53.2 months), the median 
OS of the 62 patients was 23.6 months (95% CI: 14.4–32.8; 
Figure 1). The OS rate at 1 year and 2 years was 73.0% and 
49.7%, respectively. Eleven patients achieved PR, and no 
patients had complete response, yielding an ORR of 17.7%. 
SD was observed in 21 (33.9%) patients, and thus disease 
control was observed in 33 (53.2%) patients. The DCB 
rate was 29.0%. Among the 11 patients with a confirmed 
objective response, the median time to response was 9 weeks 
(range, 4–47 weeks), and the median duration of response 
was 16.2 months (95% CI: 10.3–22.1). The median PFS 
was 2.1 months (95% CI: 1.2–3.0; Figure 1). 
The DCB rate was significantly higher in patients with 
CHB than in those with RHB (60% vs. 23.1%; P=0.048). 
The CHB group received more clinical benefit from anti-
PD-(L)1 monotherapy as compared to the RHB group, in 
terms of ORR (40% vs. 13.5%; P=0.119), DCR (80% vs. 
46.2%; P=0.106), median PFS (8.3 vs. 2.0 months; P=0.103), 
and OS (35.0 vs. 18.2 months; P=0.119). These results are 
shown in Table 3 and Figure 1.
Discussion
PD-1 pathway inhibitors have become a cornerstone in the 
treatment of patients with nononcogene addicted advanced 
Table 3 The comparison of safety and efficacy of PD-1/PD-L1 immunotherapy between the HBsAg-positive group and the HBsAg-negative but 
HBcAb-positive group
Characteristics Total, n (%) (n=62)
HBsAg-positive group, 
 n (%) (n=10)
HBsAg-negative and HBcAb-
positive group, n (%) (n=52)
OR (95% CI) P valuea
All grades AEs 42 (67.7) 8 (80.0) 34 (65.4) 2.12 (0.41–11.04) 0.592
Hepatic AEs 6 (9.7) 5 (50.0) 1 (1.9) 51 (4.94–526.95) <0.001
ORR 11 (17.7) 4 (40.0) 7 (13.5) 4.29 (0.96–19.11) 0.119
DCR 32 (51.6) 8 (80.0) 24 (46.2) 4.67 (0.90–24.12) 0.106
DCB 18 (29.0) 6 (60.0) 12 (23.1) 5.00 (1.21–20.69) 0.048
 a, determined using the χ2 test. AE, adverse event; PD-1, programmed cell death protein-1; PD-L1, programmed cell death-ligand 1; 
HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; OR, odds ratio; CI, confidence Interval; ORR, objective response 
rate; DCR, disease control rate; DCB, durable clinical benefit.
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NSCLC. However, patients with HBV infection have 
systematically been excluded from immunotherapy clinical 
trials, limiting our understanding concerning the safety and 
efficacy of immune checkpoints inhibitors (ICIs) among 
these patients. Several case reports have demonstrated that 
PD-(L)1 inhibitors can be safe and effective in NSCLC 
patients with either chronic HBV or HCV infection (14-20). 
Most of the relevant studies have enrolled a limited number 
of patients, impeding in-depth characterization of the 
safety and efficacy of immunotherapy. To the best of our 
knowledge, this is the largest study to detail the safety and 
efficacy of PD-(L)1 inhibitors in patients with advanced 
NSCLC and different HBV infection status. Our results 
showed that anti-PD-(L)1 monotherapy yielded similar 
efficacy outcomes in NSCLC patients with HBV infection 
as those observed in patients without HBV (2-4,31). The 
incidence of all-grade hepatic AEs in this cohort (9.7%) 
seems to be slightly higher than that reported in previous 
clinical trials (4-6,32), while other AE profiles were similar. 
HBV reactivation was identified in 1 CHB patient during 
anti-PD-1 therapy after the antiviral agent was stopped by 
the patient.
In the CA209-003 study involving HBV-negative 
NSCLC patients who had received at least 1 prior systemic 
anticancer regimen, the response rate to nivolumab 
monotherapy was 17%, with a median duration of response 
of 17.0 months (33,34), a median OS of 9.9 months, 
and 1-, 2-, and 3-year OS rates of 42%, 24%, and 18%, 
Figure 1 Kaplan-Meier analysis of overall survival (OS) and progression-free survival (PFS). (A) OS of 62 enrolled patients. (B) PFS of 62 
































































































Time (month) Time (month)
Time (month)
Number at risk
Number at risk Number at risk
Number at risk
0 10 20 30 40 50
0 10 20 30 40 50 0 10 20 30 40 50
0 10 20 30 40 50
62 38 23 12 62 148 1 8 2 1 1
Median OS 23.6 months (95% CI, 14.4–32.8)
Median PFS 2.1 months (95% CI, 1.2–3.0)
All
HBsAg (+) HBsAg (+)














3198 Zhang et al. Anti-PD-1/PD-L1 immunotherapy in HBV infected NSCLC patients
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(7):3191-3202 | https://dx.doi.org/10.21037/tlcr-21-455
respectively (23,24). In our study, with 91.9% pretreated 
participants, the overall response rate was 17.7%, the 
DCB rate was 29.0%, the median duration of response was 
16.2 months, the median OS was 23.6 months, and the 1- 
and 2-year OS rates were 73.0% and 49.7%, respectively. 
Another retrospective case series enrolled 19 patients with 
NSCLC and a history of HBV or HCV infection and found 
that the ORR in 17 patients treated with immunotherapy 
alone was 35% and the median PFS was 4.5 months (18). 
These results suggest that the response rate and long-
term outcome of PD-(L)1 inhibitors in HBV-infected 
NSCLC patients appear to be similar to those without 
HBV infection. Interestingly, the clinical benefit from ICI 
among patients varied depending on the HBV infection 
status. In this study, we found that patients with chronic 
HBV infection had a significantly higher DCB rate than 
those with a resolved HBV infection (60% vs. 23.1%; 
P=0.048). There also was a tendency toward improved 
ORR and PFS in patients with chronic HBV infection. 
In a retrospective study enrolling NSCLC patients with a 
history of tuberculosis (TB) and/or HBV who were treated 
with ICI (monotherapy or combination therapy), patients in 
the group with HBV or TB appeared to have better survival 
outcomes compared with the group without, in terms of 
PFS (5.7 vs. 3.1 months; P=0.021) and OS (15.6 vs. 11.1 
months, P=0.046) (19). Of note, the group with TB or HBV 
included a higher proportion of patients receiving ICI in the 
first-line setting with PD-L1 expression ≥1%. Considering 
the retrospective nature and small sample size of the current 
study, our findings should be interpreted with caution. In 
NSCLC patients, the tumor-expressed ligands PD-L1 and 
PD-L2 engage the PD-1 receptor expressed on activated 
T cells to down-regulate T-cell activation (23). Meanwhile, 
upregulation of PD-1 on viral specific T cells from CHB 
patients has been observed and proven to be associated 
with T cell exhaustion and persistent viral infection 
(24,25). The finding of higher PD-L1 expression in tumor 
cells also indicates that there might be an HBV-mediated 
systemic immune response that could potentially affect the 
anti-/PD-(L)1 immunotherapy in NSCLC patients with 
CHB (27). PD-1 inhibitor administration might restore 
T cell function, and the cytotoxic T cells may induce 
antitumor activity more effectively in patients with CHB.
With anti-PD-(L)1 monotherapy, the incidence of 
hepatic AEs in HBV-negative NSCLC patients is about 6% 
or less in reported studies, with grade 3–4 events occurring 
in 1–2% of patients (5,32,35). These hepatic AEs consist 
mainly of asymptomatic elevations in AST and ALT levels. 
In our study, all grade and grade 3–4 hepatic AEs occurred 
in 9.7% and 1.6% of the patients, respectively. Recently, 
the nonrandomized, open-label, real-world, CheckMate870 
trial (NCT03195491), examined the safety and efficacy of 
nivolumab as second-line therapy for Asian patients with 
NSCLC (36). One of the secondary endpoints was the 
safety of nivolumab in HBV-infected patients (a total of 17 
patients required to have an HBV DNA level of lower than 
500 IU/mL). The most common grade 3–4 AEs included 
those observed in the liver (2.3%), skin (1.6%), lungs 
(1.0%), and endocrine system (0.8%). The ORR was similar 
between those with and without HBV infection (17.6% 
vs. 15.4%). Taken together, anti-PD-(L)1 monotherapy 
is generally well tolerated in patients with NSCLC and a 
concurrent HBV infection.
In addition to their antitumor activity, anti-PD-(L)1 
antibodies’ effect on the control of chronic viral infections 
is of immense interest. A clinical trial (NCT00703469) that 
assessed an anti-PD-1 antibody in patients with chronic 
HCV infection showed that some patients have persistent 
suppression of HCV replication. However, there are case 
reports or case series indicating that HBV reactivation is a 
potential complication of anti-PD-(L)1 therapy in HBV-
infected patients with cancers (16,17,19,28,37). In our 
previous pan-cancer study, we found that HBV reactivation 
occurs in 5.3% of the patients with positive HBsAg, and 
that the lack of prophylactic antiviral therapy was the 
most important risk factor [odds ratio (OR) 17.50] (28). 
In the current study, an incident of HBV reactivation 
was identified in an HBsAg-positive patient receiving 
camrelizumab. Furthermore, several isolated cases of 
anti-PD-1 immunotherapy–related HBV reactivation in 
patients with resolved HBV infection have been reported 
(16,17,37). These findings suggest that both patients with 
chronic HBV and resolved HBV infection are at risk of 
virus reactivation while receiving PD-(L)1 blockade, and 
that screening for HBV in all patients should be performed 
before treatment begins (38). It’s worth noting that, though 
widely observed in clinical practice, the mechanism of 
HBV reactivation induced by anti- PD-1/PD-L1 therapy 
is still unclear. More basic research will be needed to reveal 
the underlying mechanisms. For the patient experienced 
HBV reaction in the current study, entecavir was given as 
prophylaxis at the commencement of camrelizumab, but was 
stopped disregarding the physician’s advice after 25 cycles 
of immunotherapy. The HBV reactivation event occurred 
33 weeks after the interruption of entecavir. This 
case supports the monitoring of HBV DNA level and 
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maintenance of antiviral prophylaxis before and during 
anti-PD-(L)1 immunotherapy as a clinically important 
measure in CHB patients. A recent report indicates 
that concurrent antiviral prophylaxis might allow safe 
treatment even in patients with high HBV DNA loads 
(>500 IU/mL) (39). Our previous study also found 1 event 
of reactivation in a patient with CHB that occurred 6 weeks 
after immunotherapy was discontinued (28), implying that 
antiviral treatment should be continued even after the 
PD-(L)1 inhibitor administration has been completed. 
According to AASLD guidance (30), the administration 
of antiviral therapy should last for at least 6 months after 
completion of immunosuppressive agents or chemotherapy, 
but whether this recommendation is applicable for 
immunotherapy remains to be determined. For RHB 
patients, who are at lower risk of HBV reactivation than are 
CHB patients (19), treatment can begin on prophylaxis, or 
ALT, HBV DNA, and HBsAg can be carefully monitored 
with the intent for on-demand anti-HBV therapy (30). 
Given our experience in this real-world study, anti-PD-
(L)1 immunotherapy appears to be safe and effective in 
HBV-infected patients with NSCLC. However, further 
research is warranted to address several unanswered 
questions regarding the application of ICIs in patients with 
NSCLC and HBV infection. An in-depth characterization 
of the tumor microenvironment, especially PD-L1 
expression in NSCLC for patients with HBV, is currently 
lacking. Furthermore, the safety of ICIs in this population 
deserves further investigation with regards to serious 
immune-related AEs and particularly HBV reactivation. 
Although we had previously shown that a lack of 
prophylactic antiviral therapy is a significant risk factor 
of HBV reactivation, the underlying mechanisms remain 
unclear. Also, how HBV infection impacts the systemic 
immune response and the action of PD-(L)1 inhibitors 
in cancer patients should be further studied. Finally, the 
response patterns of anti-/PD-(L)1 therapy and factors that 
might impact the likelihood of response are also unknown. 
Some limitations to our study should be addressed. 
First, as a retrospective, single-center study, there might 
have been bias in the selection of patients. The results 
need to be further validated by future clinical studies with 
larger sample sizes. Second, only patients with CHB were 
regularly monitored for HBV DNA in this study, while 
patients with RHB were not routinely tested for HBV 
DNA before and during anti-PD-(L)1 immunotherapy. 
The lack of data concerning HBV DNA level could have 
resulted in an underdetection of the reactivation events 
in these patients. Given its clear value in monitoring 
viral reactivation in HBV-infected patients, we advise 
incorporating baseline and on-treatment HBV DNA levels 
into routine clinical practice. Finally, the measurement 
of tumoral PD-L1 expression was not performed in most 
patients. Thus, we could not further evaluate the association 
between HBV infection and PD-L1 expression in NSCLC 
patients. 
Conclusions
Our study indicates that anti-PD-(L)1 immunotherapy could 
be safe and effective in HBV-infected patients. Patients 
with positive HBsAg (chronic HBV infection) were more 
likely to have durable benefit than those with resolved HBV 
infection. HBV reactivation may occur upon treatment 
with PD-(L)1 inhibitors, and this should be monitored 
attentively throughout the therapeutic process. Our findings 
support the use of anti-PD-(L)1 immunotherapy in these 
patients, along with regular monitoring of HBV serological 
markers and properly administrated antiviral prophylaxis to 
prevent HBV reactivation. Future clinical trials of anti-PD-
(L)1 immunotherapy should not exclude patients with HBV 
infection. Further studies are needed to better characterize 
the response patterns of immunotherapy in this special 
population of HBV-infected patients.
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